Affinity Asset Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Affinity Asset Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-136,434	Closed	-$2.15M	–	64
2022 Q3	$2.15M	Buy	136,434 +36,434	+36%	+$574K	0.6%	38
2022 Q2	$1.4M	Hold	100,000	–	–	0.59%	36
2022 Q1	$1.72M	Sell	100,000 -300,000	-75%	-$4.09M	0.28%	41
2021 Q4	$5.82M	Buy	400,000 +50,000	+14%	+$758K	2.11%	18
2021 Q3	$6.3M	Buy	350,000 +75,000	+27%	+$1.2M	1.59%	13
2021 Q2	$4.83M	Buy	275,000 +52,733	+24%	+$1.2M	1.73%	18
2021 Q1	$5.6M	Buy	+222,267	New	+$4.35M	1.9%	12

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Affinity Asset Advisors's ACRS Position: Q4 2022 in Review

Affinity Asset Advisors sold out of Aclaris Therapeutics (ACRS) in Q4 2022, closing a stake of 136,434 shares — an estimated $2.15M sold.

Affinity Asset Advisors first reported a position in ACRS in Q1 2021 and held it in 7 quarters. The position peaked at $6.3M in Q3 2021. 128 funds tracked by Wall St. Rank hold ACRS as of Q4 2022.

Affinity Asset Advisors reported no remaining Aclaris Therapeutics position as of Q4 2022 after selling out during the quarter.
Affinity Asset Advisors sold 136,434 Aclaris Therapeutics shares in Q4 2022, an estimated $2.15M.
Affinity Asset Advisors first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 7 quarters.
Affinity Asset Advisors's Aclaris Therapeutics position peaked at $6.3M in Q3 2021.
128 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2022.

Based on Affinity Asset Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.